natgillin/translations-raw huggingface dataset:
Information obtained from cases involving death also suggests that users unknowingly consumed 4,4′-DMAR when seeking other stimulants.
Prikupljene informacije o smrtnim slučajevima također ukazuju na to da su korisnici nesvjesno konzumirali tvar 4,4′-DMAR u potrazi za drugim stimulansima.
There is limited involvement of organised crime in the manufacture, distribution, trafficking and supply of 4,4′-DMAR within the Union.
Sudjelovanje organiziranog kriminala u proizvodnji, distribuciji, nedopuštenoj trgovini tvari 4,4′-DMAR i opskrbi njome u Uniji ograničeno je.
The chemical precursors and the synthetic routes used to manufacture 4,4′-DMAR are unknown.
Nisu poznati kemijski prekursori i metode sinteze koji se upotrebljavaju za proizvodnju tvari 4,4′-DMAR.
4,4′-DMAR is not listed for control under the 1961 United Nations Single Convention on Narcotic Drugs or under the 1971 United Nations Convention on Psychotropic Substances.
Tvar 4,4′-DMAR ne nalazi se na popisu tvari koje treba kontrolirati na temelju Jedinstvene konvencije Ujedinjenih naroda o opojnim drogama iz 1961. ili na temelju Konvencije Ujedinjenih naroda o psihotropnim tvarima iz 1971.
It is not currently under assessment, and has not been under assessment, by the United Nations' system, and no such assessment is planned.
Ona u okviru sustava Ujedinjenih naroda nije bila pod procjenom, trenutačno nije pod procjenom niti se takvu procjenu planira.
4,4′-DMAR has no established or acknowledged human or veterinary medical use in the Union.
Tvar 4,4′-DMAR nema utvrđenu ili dokazanu uporabu u humanoj ili veterinarskoj medicini u Uniji.
Apart from its use in analytical reference materials, and in scientific research investigating its chemistry, pharmacology and toxicology, there is no indication that it is being used for other purposes.
Osim njezine uporabe u analitičkim referentnim materijalima i u znanstvenim istraživanjima u kojima se proučavaju njezina kemijska, farmakološka i toksikološka svojstva, nema nikakvih naznaka da se upotrebljava za druge svrhe.
The Risk Assessment Report reveals that there is limited scientific evidence available on 4,4′-DMAR and points out that further research would be needed to determine the health and social risks that it poses.
Iz izvješća o procjeni rizika proizlazi da su dostupni ograničeni znanstveni dokazi o tvari 4,4′-DMAR te se u njemu ističe da će biti potrebno daljnje istraživanje kako bi se utvrdili zdravstveni i socijalni rizici koje ona predstavlja.
However, the evidence and information currently available provides sufficient ground for subjecting 4,4′-DMAR to control measures across the Union.
Međutim, trenutačno dostupni dokazi i informacije predstavljaju dovoljnu osnovu za podvrgavanje tvari 4,4′-DMAR kontrolnim mjerama diljem Unije.
As a result of the risks to health that the consumption of 4,4′-DMAR poses, as documented by its detection in several fatalities, of the fact that users may unknowingly consume it, and of the lack of medical value of this substance, 4,4′-DMAR should be subjected to control measures.
Zbog zdravstvenih rizika koje predstavlja konzumacija tvari 4,4′-DMAR, kao što je dokumentirano njezinim otkrivanjem u više smrtnih slučajeva, činjenice da je korisnici mogu nesvjesno konzumirati i nepostojanja medicinske vrijednosti te tvari, tvar 4,4′-DMAR trebalo bi podvrgnuti kontrolnim mjerama.
Given that three Member States control 4,4′-DMAR under national legislation complying with the obligations of the 1971 United Nations Convention on Psychotropic Substances and five Member States use other legislative measures to control it, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would protect against the risks that its availability and use can pose.
S obzirom na to da tri države članice kontroliraju tvar 4,4′-DMAR u okviru nacionalnog zakonodavstva kojim se poštuju obveze iz Konvencije Ujedinjenih naroda o psihotropnim tvarima iz 1971. i da pet država članica upotrebljava druge zakonodavne mjere za njezinu kontrolu, podvrgavanje te tvari kontrolnim mjerama širom Unije pomoglo bi izbjegavanju pojave prepreka u prekograničnom izvršavanju zakona i pravosudnoj suradnji te bi pružilo zaštitu od rizika koje dostupnost i uporaba te tvari mogu predstavljati.
A Risk Assessment Report on the new psychoactive substance 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45) was drawn up in accordance with Article 6(2), (3) and (4) of Decision 2005/387/JHA by a special session of the extended Scientific Committee of the EMCDDA, and was subsequently submitted to the Commission and to the Council on 6 October 2014.
Izvješće o procjeni rizika za novu psihoaktivnu tvar 1-cikloheksil-4-(1,2-difeniletil)piperazin (MT-45) sastavljeno je u skladu s člankom 6. stavcima 2., 3. i 4. Odluke 2005/387/PUP na posebnoj sjednici proširenog Znanstvenog odbora EMCDDA-a te je naknadno podneseno Komisiji i Vijeću 6. listopada 2014.
MT-45 is an N,N′-disubstituted piperazine, having a cyclohexane ring attached to one of the nitrogen atoms of the piperazine ring and a 1,2-diphenylethyl moiety attached to the other nitrogen atom.
Tvar MT-45 je N,N′-disupstituirani piperazin koji posjeduje cikloheksanski prsten povezan s jednim atomom dušika na piperazinskom prstenu i funkcionalnu grupu 1,2-difeniletila povezanu s drugim atomom dušika.
MT-45 is one of a series of 1-(1,2-diphenylethyl)piperazine analgesics invented in the early 1970s.
Tvar MT-45 jedan je u nizu 1-(1,2-difeniletil) piperazinskih analgetika otkrivenih u ranim sedamdesetim godinama 20. stoljeća.
MT-45 has been present on the drugs market in the Union since October 2013, where it is sold as a ‘research chemical’, mostly on the internet.
U Uniji je tvar MT-45 od listopada 2013. prisutna na tržištu droga na kojem se prodaje kao „istraživačka kemikalija”, uglavnom putem interneta.
The EMCDDA has identified 12 sites of internet suppliers and retailers that have offered MT-45 for sale, including some apparently based in the Union.
EMCDDA je identificirao 12 internetskih stranica internetskih opskrbljivača i prodavatelja koji su nudili tvar MT-45 na prodaju, uključujući pojedine čije je sjedište očito u Uniji.
Some 18 non-fatal intoxications have also been reported by the same Member State, the clinical features of which were similar to opioid intoxication, responding in some cases to the opioid receptor antagonist naloxone.
Ista država članica prijavila je i 18 trovanja bez smrtnih posljedica čija su klinička svojstva slična trovanju opiodima, a u pojedinim slučajevima odgovaraju antagonistu opiodinih receptora naloksonu.
There are several studies in animals indicating that the acute toxicity of MT-45 is several-fold higher than that of morphine.
Više istraživanja na životinjama pokazuju da je akutna toksičnost tvari MT-45 nekoliko puta veća od toksičnosti morfija.
Currently available information suggests that MT-45 has not been widely used.
Trenutačno dostupne informacije ukazuju na to da tvar MT-45 nije u raširenoj uporabi.
The substance appears to be mostly used in the home environment either by users willing to try a new substance or by opioid dependent users with no access to heroin or any other opioid.
Čini se da tu tvar uglavnom u domu upotrebljavaju ili osobe spremne na isprobavanje nove tvari ili ovisnici o opioidima koji nemaju pristup heroinu ili nekom drugom opioidu.
Users may combine MT-45 with other psychoactive substances.
Korisnici mogu kombinirati tvar MT-45 s drugim psihoaktivnim tvarima.
There is no information on the social risks that may be related to MT-45.
Nema informacija o socijalnim rizicima koji se mogu povezati s tvari MT-45.
There is no evidence of involvement of organised crime in the manufacture, distribution, trafficking and supply of MT-45 in the Union.
Ne postoje dokazi o sudjelovanju organiziranog kriminala u proizvodnji, distribuciji, nedopuštenoj trgovini tvari MT-45 i opskrbi njome u Uniji.
The chemical precursors and the synthetic routes used to manufacture the MT-45 detected in Member States are unknown.
Nisu poznati kemijski prekursori i metode sinteze koji se upotrebljavaju za proizvodnju tvari MT-45 koja je otkrivena u državama članicama.
MT-45 is not listed for control under the 1961 United Nations Single Convention on Narcotic Drugs or under the 1971 United Nations Convention on Psychotropic Substances.
Tvar MT-45 ne nalazi se na popisu tvari koje treba kontrolirati na temelju Jedinstvene konvencije Ujedinjenih naroda o opojnim drogama iz 1961. ili Konvencije Ujedinjenih naroda iz 1971. o psihotropnim tvarima.
MT-45 has no established or acknowledged human or veterinary medical use in the Union.
Tvar MT-45 nema utvrđenu ili priznanu uporabu humanoj ili veterinarskoj medicini u Uniji.
The Risk Assessment Report reveals that there is limited scientific evidence available on MT-45 and points out that further research would be needed to determine the health and social risks that it poses.
Iz izvješća o procjeni rizika proizlazi da su dostupni ograničeni znanstveni dokazi o tvari MT-45 te se u njemu ističe da će biti potrebno daljnje istraživanje kako bi se utvrdili zdravstveni i socijalni rizici koje ona predstavlja.
However, the evidence and information currently available provides sufficient grounds for subjecting MT-45 to control measures across the Union.
Međutim, trenutačno dostupni dokazi i informacije predstavljaju dovoljnu osnovu za podvrgavanje tvari MT-45 kontrolnim mjerama širom Unije.
As a result of the health risks that it poses, as documented by its detection in several fatalities, and of the lack of medical value of this substance, MT-45 should be subjected to control measures.
Zbog zdravstvenih rizika koje tvar MT-45 predstavlja, kao što je dokumentirano njezinim otkrivanjem u više smrtnih slučajeva i nepostojanja medicinske vrijednosti te tvari, tvar MT-45 trebalo bi podvrgnuti kontrolnim mjerama.
Given that one Member State controls MT-45 under national legislation complying with the obligations under the 1961 United Nations Single Convention on Narcotic Drugs and under the 1971 United Nations Convention on Psychotropic Substances and seven Member States use other legislative measures to control it, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would protect against the risks that its availability and use can pose.
S obzirom na to da jedna država članica kontrolira tvar MT-45 u okviru nacionalnog zakonodavstva kojim se poštuju obveze na temelju Jedinstvene konvencije Ujedinjenih naroda o opojnim drogama iz 1961. i na temelju Konvencije Ujedinjenih naroda o psihotropnim tvarima iz 1971. i da sedam država članica upotrebljava druge zakonodavne mjere za njezinu kontrolu, podvrgavanje te tvari kontrolnim mjerama širom Unije pomoglo bi izbjegavanju pojave prepreka u prekograničnom izvršavanju zakona i pravosudnoj suradnji te bi pružilo zaštitu od rizika koje dostupnost i uporaba te tvari mogu predstavljati.
Decision 2005/387/JHA confers upon the Council implementing powers with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union.
Odlukom 2005/387/PUP Vijeću se dodjeljuju provedbene ovlasti s ciljem davanja brzog i stručno utemeljenog odgovora na razini Unije na pojavu novih psihoaktivnih tvari koje su otkrile i prijavile države članice, podvrgavanjem tih tvari kontrolnim mjerama širom Unije.
As the conditions and procedure for triggering the exercise of such implementing powers have been met, an implementing decision should be adopted in order to put 4,4′-DMAR and MT-45 under control across the Union.
Budući da su ispunjeni uvjeti i postupak za pokretanje izvršavanja takvih provedbenih ovlasti, trebalo bi donijeti provedbenu odluku kako bi se tvari 4,4′-DMAR i MT-45 stavile pod kontrolu diljem Unije.
Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
Odluka 2005/387/PUP obvezuje Dansku te ona stoga sudjeluje u donošenju i primjeni ove Odluke kojom se provodi Odluka 2005/387/PUP.
Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision which implements Decision 2005/387/JHA.
Odluka 2005/387/PUP obvezuje Irsku te ona stoga sudjeluje u donošenju i primjeni ove Odluke kojom se provodi Odluka 2005/387/PUP.
The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not taking part in the adoption of this Decision which implements Decision 2005/387/JHA and is not bound by it or subject to its application,
Odluka 2005/387/PUP ne obvezuje Ujedinjenu Kraljevinu te ona stoga ne sudjeluje u donošenju ove Odluke kojom se provodi Odluka 2005/387/PUP, ova Odluka je ne obvezuje niti se na nju primjenjuje,
The following new psychoactive substances shall be subjected to control measures across the Union:
Sljedeće nove psihoaktivne tvari podvrgavaju se kontrolnim mjerama diljem Unije:
ethyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-DMAR);
etil-5-(4-metilfenil)-4,5-dihidrooksazol-2-amin (4,4′-DMAR);
yclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45).
ikloheksil-4-(1,2-difeniletil)piperazin (MT-45).
By 21 October 2016, Member States shall take the necessary measures, in accordance with their national law, to subject the new psychoactive substances referred to in Article 1 to control measures and criminal penalties, as provided for under their legislation complying with their obligations under the 1961 United Nations Single Convention on Narcotic Drugs and/or under the 1971 United Nations Convention on Psychotropic Substances.
Do 21. listopada 2016. države članice poduzimaju potrebne mjere, u skladu sa svojim nacionalnim zakonodavstvom, za podvrgavanje novih psihoaktivnih tvari iz članka 1. kontrolnim mjerama i kaznenim sankcijama, kako je predviđeno u njihovom zakonodavstvu kojim se poštuju njihove obveze na temelju Jedinstvene konvencije Ujedinjenih naroda o opojnim drogama iz 1961. i/ili na temelju Konvencije Ujedinjenih naroda o psihotropnim tvarima iz 1971.
This Decision shall apply in accordance with the Treaties.
Ova Odluka primjenjuje se u skladu s Ugovorima.
Done at Luxembourg, 8 October 2015.
Sastavljeno u Luxembourgu 8. listopada 2015.
4,4′-DMAR has been available on the drugs market in the Union since at least December 2012 and was notified to the Early Warning System in December 2012.
Tvar 4,4′-DMAR dostupna je na tržištu droga u Uniji barem od prosinca 2012. te je u prosincu 2012. prijavljena putem sustava za rano uzbunjivanje.
Nine Member States have reported detections as a result of seizures of the substance, mainly in the form of white or coloured powders and tablets, as well as biological and collected samples.
Devet država članica prijavilo je otkrivanja tvari pri pljenidbama, uglavnom u obliku bijelih ili obojanih prašaka i tableta, kao i bioloških i prikupljenih uzoraka.
There have been 31 deaths associated with 4,4′-DMAR registered in three Member States, between June 2013 and June 2014.
Između lipnja 2013. i lipnja 2014. zabilježen je 31 smrtni slučaj povezan s tvari 4,4′-DMAR u trima državama članicama.
In most cases, 4,4′-DMAR was either the cause of death or, together with other substances, is likely to have contributed to death.
U većini slučajeva tvar 4,4′-DMAR bila je ili uzrok smrti ili je, zajedno s drugim tvarima, vjerojatno doprinijela smrti.
A total of 28 fatalities occurring between November 2013 and July 2014 have been reported by one Member State.
Jedna država članica prijavila je ukupno 28 smrtnih slučajeva do kojih je došlo između studenoga 2013. i srpnja 2014.
In most cases, the presence of MT-45 in biological samples was analytically confirmed.
U većini je slučajeva u biološkim uzorcima analizom potvrđena prisutnost tvari MT-45.
Council Implementing Decision (EU) 2015/1874
Provedbena odluka Vijeća (EU) 2015/1874
on subjecting 4-methylamphetamine to control measures
o podvrgavanju 4-metilamfetamina kontrolnim mjerama
A Risk Assessment Report on 4-methylamphetamine was drawn up in accordance with Article 6 of Decision 2005/387/JHA by a special session of the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and was subsequently received by the Commission on 29 November 2012.
Izvješće o procjeni rizika za tvar 4-metilamfetamin sastavljeno je, u skladu s člankom 6. Odluke 2005/387/PUP, na posebnoj sjednici proširenog Znanstvenog odbora Europskog centra za praćenje droga i ovisnosti o drogama (EMCDDA) te ga je Komisija naknadno primila 29. studenoga 2012.
ethylamphetamine is a synthetic ring-methylated derivative of amphetamine which has predominantly been seized in powder and paste form in samples containing amphetamine and caffeine, but which has also appeared in tablet and liquid form.
Tvar 4-metilamfetamin je sintetički derivat amfetamina s metiliranim benzenovim prstenom koja većinom biva zaplijenjena u obliku praška ili paste u uzorcima koji sadrže amfetamin i kofein, ali se također pojavljuje u obliku tableta i u tekućem obliku.
It has emerged on the illicit amphetamine market where it is sold and used as the controlled drug, amphetamine.
Pojavila se na nezakonitom tržištu amfetamina na kojem se prodaje i upotrebljava kao kontrolirana droga amfetamin.
There has been one report of the substance being detected in a commercial product sold on the internet.
U jednom je izvješću navedeno da je ta tvar otkrivena u komercijalnom proizvodu koji se prodaje putem interneta.
The main chemical precursor for the synthesis of 4-methylamphetamine is 4-methylbenzyl methyl ketone (4-methyl-BMK), which appears to be commercially available on the internet and is not controlled under the 1988 United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.
Glavni kemijski prekurzor za sintezu 4-metilamfetamina jest 4-metilbenzil-metilni keton (4-metil-BMK) koji je vjerojatno komercijalno dostupan na internetu i ne nalazi se pod kontrolom na temelju Konvencije Ujedinjenih naroda protiv nezakonite trgovine opojnim drogama i psihotropnim tvarima iz 1988.
The specific physical effects of 4-methylamphetamine have been rarely reported by users, since users are typically unaware that they have taken the substance.
Korisnici rijetko prijavljuju specifične fizičke učinke 4-metilamfetamina jer oni uglavnom nisu ni svjesni da su ga konzumirali.
However, the few reports that are available suggest that it has stimulant-type effects.
Međutim, malobrojna dostupna izvješća ipak ukazuju na to da on ima stimulirajuće učinke.
Limited data available relating to humans suggest that the adverse effects of 4-methylamphetamine include hyperthermia, hypertension, anorexia, nausea, perspiration, gastric distress, coughing, vomiting, headache, palpitations, insomnia, paranoia, anxiety and depression.
Ograničeni dostupni podaci koji se odnose na ljude ukazuju na to da negativni učinci 4-metilamfetamina uključuju povišenu temperaturu, povišeni krvni tlak, anoreksiju, mučninu, znojenje, želučane tegobe, kašljanje, povraćanje, glavobolju, palpitaciju, nesanicu, paranoju, tjeskobu i depresiju.
Current data is not sufficient to determine the relative dependence-producing potential of the substance.
Trenutačni podaci nisu dostatni za utvrđivanje relativnog potencijala koji ta tvar ima za izazivanje ovisnosti.
According to the limited data sources available, the acute toxicity of 4-methylamphetamine is similar to that of other stimulants.
Prema ograničenim izvorima podataka koji su dostupni, akutna toksičnost 4-metilamfetamina slična je onoj drugih stimulansa.
Certain evidence suggests that a combination of 4-methylamphetamine with other substances, including amphetamine and caffeine, may result in a higher risk of overall enhanced toxicity.
Određeni dokazi ukazuju na to da kombiniranje 4-metilamfetamina s drugim tvarima, uključujući amfetamin i kofein, može prouzročiti povećani rizik od ukupno pojačane toksičnosti.
There have been a total of 21 fatalities registered in four Member States where 4-methylamphetamine alone, or in combination with one or more substances, especially amphetamine, has been detected in post-mortem samples.
U četiri države članice zabilježen je ukupno 21 smrtni slučaj u kojem je 4-metilamfetamin sam ili u kombinaciji s jednom ili više drugih tvari, posebno amfetaminom, otkriven u obdukcijskim uzorcima.
While it is not possible to determine with certainty from the information available the role of 4-methylamphetamine in those fatalities, in some cases the substance was the predominant drug detected, with levels comparable to those found in certain cases of death caused by the consumption of amphetamine.
Iako iz dostupnih informacija nije moguće sa sigurnošću odrediti ulogu 4-metilamfetamina u tim smrtnim slučajevima, u pojedinim je slučajevima ta tvar bila droga koja je otkrivena u najvećim količinama, pri čemu su utvrđene razine usporedive s onim razinama koje su utvrđene u određenim smrtnim slučajevima prouzročenima konzumacijom amfetamina.
ethylamphetamine has been detected in 15 Member States, while one Member State has reported the manufacture of the substance on its territory.
Tvar 4-metilamfetamin otkrivena je u 15 država članica, a jedna država članica prijavila je proizvodnju te tvari na svojem državnom području.
Prevalence specific to 4-methylamphetamine is difficult to estimate.
Raširenost 4-metilamfetamina teško je procijeniti.
There is no information on specific demand for the substance from user groups and it is not commercially marketed through internet shops.
Ne postoje informacije o specifičnoj potražnji skupina korisnika za tom tvari i ona nije komercijalno dostupna na tržištu putem internetskih trgovina.
The information available suggests that 4-methylamphetamine is produced and distributed by the same organised crime groups that are involved in the manufacture and trafficking of amphetamine.
Dostupne informacije ukazuju na to da 4-metilamfetamin proizvode i distribuiraju iste skupine organiziranog kriminala koje su uključene u proizvodnju amfetamina i nezakonitu trgovinu njime.
ethylamphetamine has no known, established or acknowledged medical value or use in the Union and there is no marketing authorisation for the substance in the Union.
Tvar 4-metilamfetamin nema poznatu, dokazanu ili priznatu medicinsku vrijednost ili uporabu u Uniji niti ima odobrenje za stavljanje na tržište u Uniji.
Apart from its use as an analytical reference standard and in scientific research, there is no indication that it may be used for any other legitimate purpose.
Osim njezine uporabe kao analitičkog referentnog standarda i uporabe u znanstvenim istraživanjima, nema nikakvih naznaka da bi se nju moglo upotrebljavati za bilo koje druge zakonite svrhe.
ethylamphetamine is not currently under assessment and has not been under assessment by the United Nations' system.
Tvar 4-metilamfetamin trenutačno nije pod procjenom niti je bila pod procjenom u okviru sustava Ujedinjenih naroda.
The Risk Assessment Report reveals that there is limited scientific evidence available on the characteristics and risks of 4-methylamphetamine and points out that further studies are required on the overall health and social risks associated with the substance.
Iz izvješća o procjeni rizika proizlazi da su dostupni ograničeni znanstveni dokazi o svojstvima i rizicima 4-metilamfetamina te se u njemu ističe da su potrebne daljnje studije o ukupnim zdravstvenim i socijalnim rizicima povezanima s tom tvari.
However, the evidence available provides sufficient grounds for subjecting 4-methylamphetamine to control measures across the Union.
Međutim, dostupni dokazi pružaju dostatne razloge za podvrgavanje 4-metilamfetamina kontrolnim mjerama širom Unije.